BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LAE102 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LAE102\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06493084-242@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:LAE102: Phase 1 readout est. (NCT06493084)
DESCRIPTION:LAE102\, phase 1\, Obesity.\nStudy: Evaluate LAE102 in Healthy 
 and Overweight/Obese Subjects\nEstimated primary completion: 30 June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/lae102#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06493084
URL:https://assetmemo.bio/drug/lae102#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671391-242@assetmemo.bio
DTSTAMP:20261121T004041Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:LAE102: Phase 2 readout est. (NCT07671391)
DESCRIPTION:LAE102\, phase 2\, Obesity.\nStudy: A Randomized\, Double-blind
 \, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in C
 ombination With Tirzepatide on Body in Obese Participants\nEstimated prima
 ry completion: July 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lae102#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07671391
URL:https://assetmemo.bio/drug/lae102#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
